A British mother of three had part of her lung removed after being misdiagnosed with cancer, before she was told two weeks ...
A woman who had part of her lung removed after being misdiagnosed with cancer has said she has been left with permanent ...
Pulmonx Corporation (Nasdaq: LUNG) ('Pulmonx” or the 'Company'), a global leader in minimally invasive treatments for lung ...
HONG KONG SAR - Media OurReach Newswire - 13 November 2025 - Citi hosted its 2025 China Conference this week and released an updated research report on Fosun ...
Cassava Sciences, Inc. (NASDAQ: SAVA, "Cassava", the "Company"), a biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders such as ...
Updated clinical results from Phase 2 pivotal portion of the PYNNACLE study evaluating rezatapopt featured in late-breaking oral presentation at the 2025 AACR-NCI-EORTC International Conference on ...
Enrollment ongoing in Phase 2 KOURAGE trial of Auxora in acute kidney injury (AKI) with respiratory failure; data expected in 1H 2026 Positive discussions with FDA ...
Canadian Association of Physicians for the Environment are raising awareness about data suggesting adverse health outcomes of ...
The weeks leading up to a major surgery can be a time of uncertainty and worry for patients, many of whom anticipate the need ...
For anaesthetists, optimising ventilation settings during surgery is a fundamental aspect of patient care. Adjusting positive ...
Pneumonia, a largely preventable disease, caused more than two million deaths in 2021, according to the Global Burden of ...
5hon MSN
Pulmonx outlines $89M–$90M 2025 guidance with renewed focus on execution and cost discipline
The CEO committed to "realign spending with growth expectations to put ourselves back on a sustainable path to profitability," and announced a "deliberate bottoms-up approach to shaping our plan," ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results